The efficacy of anastrozole in the treatment of pubertal gynecomastia in adolescent boys and in the treatment of precocious puberty in girls with McCune-Albright syndrome has not been demonstrated.
- TRADE NAME: Arimidex (AstraZeneca)
- INDICATIONS: Breast carcinoma (localized – advanced or metastatic)
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Aromatase inhibitor
- HALF-LIFE: 50 hours
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of anastrozole in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/07/2024
